DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The author estimates that in 2018, there were 86,600 incident cases of ALL worldwide, and expects that number to increase to 93,500 incident cases by 2027.
- Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
- The greatest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in Phase III.
- Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral formulations.
- The only high-impact upcoming event for drugs in the ALL space is topline Phase II trial results for Isatuximab. The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 40 licensing and asset acquisition deals involving ALL drugs during 2014-19. The $1,220m strategic collaboration agreement signed in 2018 between Fate Therapeutics and Ono Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates was the largest deal.
- The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.
- The US has a substantial lead in the number of ALL clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the ALL space is dominated by completed trials. Novartis has the highest number of completed clinical trials for ALL, with 41 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.
Key Topics Covered:
2. Key Takeaways
3. Disease Background
- Patient segmentation
- Risk factors
- TKI therapy
- Radiation therapy
- Stem cell transplant
6. Marketed Drugs
7. Pipeline Drugs
8. Recent Events and Analyst Opinion
- Blincyto for ALL (September 24, 2019)
- Copiktra for ALL (July 25, 2019)
- KTE-X19 for ALL (June 1, 2019)
- Copiktra for ALL (March 6, 2019)
- Marqibo for ALL (January 17, 2019)
- AFM11 for ALL (December 3, 2018)
- KTE-X19 for ALL (December 3, 2018)
- AUTO3 for ALL (December 2, 2018)
- Xpovio for ALL (December 1, 2018)
- AFM11 for ALL (October 8, 2018)
- ERY-ASP for ALL (June 24, 2018)
- KTE-X19 for ALL (June 4, 2018)
9. Key Upcoming Events
10. Key Regulatory Events
- Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T
- Measuring 'Minimal Residual Disease' With NGS
11. Probability of Success
12. Licensing and Asset Acquisition Deals
- CASI Acquires Global Rights To Juventas' Anti-CD19 Therapy
13. Parent Patents
14. Revenue Opportunity
15. Clinical Trial Landscape
- Sponsors by status
- Sponsors by phase
- Recent events
- Prescription information
- Fate Therapeutics
- Ono Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/r/b9bd22